Enter Note Done
Go to previous page in this tab
Session
  • Presentation | Lipid Landscapes and Therapeutic Frontiers: Metabolism, Biomarkers, and Novel Lipoprotein-Targeted Therapies
  • Basic
  • Bookmark Icon
  • BPR-32360402, a Single-Molecule Liver-Directed Dual PCSK9/LPA RNAi Therapeutic, Achieves Durable and Comprehensive Atherogenic Lipoprotein Reduction in Non-Human Primates
  • Schedule
    Notes
  • MDP0672
    Set Timezone
  •  
    View Map

Generic 'disconnected' Message
Yu Chen, Brilliant Pharmaceuticals, Chengdu, China; YANG LING, Chengdu Brilliant Pharmaceutical Co., Ltd., Chengdu, China; XIWEN CHENG, Chengdu Brilliant Pharmaceuticals, Chengdu, China; Teng Ai, jiachuan duan, haoxi huang, Brilliant Pharmaceuticals, Chengdu, China
Communities
Navigation
Session Type
Onsite Viewing
Main Session